Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Author： Yardley Denise   Noguchi Shinzaburo   Pritchard Kathleen   Burris Howard   Baselga José   Gnant Michael   Hortobagyi Gabriel   Campone Mario   Pistilli Barbara   Piccart Martine   Melichar Bohuslav   Petrakova Katarina   Arena Francis   Erdkamp Frans   Harb Wael   Feng Wentao   Cahana Ayelet   Taran Tetiana   Lebwohl David   Rugo Hope  

Publisher： Springer Publishing Company

ISSN： 0741-238X

Source： Advances in Therapy, Vol.30, Iss.10, 2013-10, pp. : 870-884

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

By Campone Mario   Beck J. Thaddeus   Gnant Michael   Neven Patrick   Pritchard Kathleen I.   Bachelot Thomas   Provencher Louise   Rugo Hope S.   Piccart Martine   Hortobagyi Gabriel N.   Nunzi Martina   Heng Daniel Y.C.   Baselga José   Komorowski Anna   Noguchi Shinzaburo   Horiguchi Jun   Bennett Lee   Ziemiecki Ryan   Zhang Jie   Cahana Ayelet   Taran Tetiana   Sahmoud Tarek   Burris Howard A.  

Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. : 1463-1473

Informa Healthcare

Access to resources Recommend Favorite

Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2847-2854

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 55-61

Karger

Access to resources Recommend Favorite

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-02 ,pp. : 101-105

Karger

Access to resources Recommend Favorite

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite